DocGo stock rose 2.4% in after-hours trading to reach $0.727 following the company's second-quarter 2026 earnings release. Analysts had expected a quarterly loss of 15 cents per share. The company's management conference call is scheduled for 5:00 p.m. ET.
DocGo had requested a short SEC extension to file its June 30, 2026 Form 10-Q, citing extra time needed for financial statement and disclosure review. The company does not expect significant changes in results of operations versus the prior-year period.
Earnings Expectations
Analysts' sentiment remains split, with Canaccord Genuity maintaining a Hold rating with a $1 price target, while Stifel and Needham both hold Buy ratings with targets of $2.50 and $3, respectively.
The stock has a beta of 2.07, meaning it tends to be more sensitive to market movements. The company carries the separate overhang of a 180-day Nasdaq listing compliance extension, with the company required to demonstrate adherence to exchange requirements by January 25, 2027.